Press Releases April 30, 2026 10:39 AM

Millicom (Tigo) notice of first quarter 2026 results and video conference

Millicom announces Q1 2026 results release and hosts global financial community video conference.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
TIGO

Millicom plans to release its first quarter 2026 financial results on May 12, 2026, accompanied by a video conference for the global financial community. The company provides telecommunications and digital services across Latin America under the TIGO brand and serves approximately 52 million customers.

Millicom (Tigo) notice of first quarter 2026 results and video conference
TIGO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Millicom will announce Q1 2026 results on May 12, 2026, via press release and video conference.
  • The company operates in Latin America offering mobile, fixed telecom services, pay TV, mobile financial services, and business cloud/security solutions.
  • Millicom has a significant customer base of around 52 million and employs approximately 15,000 people, with headquarters in Luxembourg and executive offices in Florida.

Millicom (Tigo) notice of first quarter 2026 results and video conference

Luxembourg, April 30, 2026 – Millicom (NASDAQ: TIGO) expects to announce its first quarter 2026 results on May 12, 2026, via a press release.

Millicom is planning to host a video conference for the global financial community on May 12, 2026, at 08:00 (New York) / 14:00 (Luxembourg) / 13:00 (London).

Registration for the interactive event is required at the following link. After registering, you will receive a confirmation email containing details about joining the video conference. Participants who wish to ask a question during the live event must notify the Investor Relations team via email to investors@millicom.com after the start of the event.

Participants may also join the conference in listen-only mode by dialing any of the following numbers and entering the Webinar ID: 869 6353 4578

US: +1 929 205 6099                                                           Sweden: +46 850 539 728

UK: +44 330 088 5830                                                         Luxembourg: +352 342 080 9265

Additional international numbers are available at the following link. Accompanying slides and a replay of the event will be available on the Millicom investors website.

For further information, please contact:

Press:Investors:Sofia Corral, Director Corporate Communications
press@millicom.comLuca Pfeifer, VP of Investor Relations
investors@millicom.com

About Millicom
Millicom (NASDAQ: TIGO) is a leading provider of fixed and mobile telecommunications services in Latin America. Through its TIGO® and Tigo Business® brands, the company provides a wide range of digital services and products, including TIGO Money for mobile financial services, TIGO Sports for local entertainment, TIGO ONEtv for pay TV, highspeed data, voice, and business-to-business solutions such as cloud and security. As of December 31, 2025, Millicom, including its Honduras Joint Venture, employed approximately 15,000 people and provided mobile and fiber-cable services through its digital highways to approximately 52 million customers, with a fiber-cable footprint over 14 million homes passed. Founded in 1990, Millicom International Cellular S.A. is headquartered in Luxembourg with principal executive offices in Doral, Florida.


Risks

  • Results may not meet market expectations leading to potential investor concern.
  • Exposure to economic and regulatory changes in Latin American markets could impact operations.
  • Competition in telecommunications and digital services from regional and global players may affect growth and profitability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026